1. National Institute for Clinical Excellence: Guidance on the use of docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer. Technol. Appraisal Guid. 26 (2001)
2. Clegg, A., Scott, D.A., Sidhu, M., et al.: A rapid and systematic review of the clinical effectiveness and cost-effectiveness of docetaxel, paclitaxel, gemcitabine and vinorelbine in non-small cell lung cancer. Health Technol. Assess. 5(32), 1–195, 55 (2001)
3. Le Lay, K., Riou-Franca, L., Launois, R.: Cost-effectiveness analysis of oral chemotherapy in ambulatory care: the example of vinorelbine. J. Econ. Méd. 20(7–8), 379–400 (2002)
4. Scottish Medicines Consortium: Approval given 6th May 2005 for the oral form of vinorelbine for first-choice treatment of stage III or IV non-small-cell lung cancer. http://www.scottishmedicines.org.uk/press/detail.asp?id=676 (2005)
5. Le Chevalier, T., Brisgand, D., Soria, J.C., et al.: Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 6(Suppl. 1), 8–11 (2001)